Global Herceptin (Trastuzumab) and Biosimilar Market Growth 2026-2032
The global Herceptin (Trastuzumab) and Biosimilar market size is predicted to grow from US$ 5065 million in 2025 to US$ 7073 million in 2032; it is expected to grow at a CAGR of 5.0% from 2026 to 2032.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
United States market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Herceptin (Trastuzumab) and Biosimilar players cover Roche, Amgen, Pfizer, Organon, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Herceptin (Trastuzumab) and Biosimilar Industry Forecast” looks at past sales and reviews total world Herceptin (Trastuzumab) and Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Herceptin (Trastuzumab) and Biosimilar sales for 2026 through 2032. With Herceptin (Trastuzumab) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Herceptin (Trastuzumab) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Herceptin (Trastuzumab) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Herceptin (Trastuzumab) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Herceptin (Trastuzumab) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Herceptin (Trastuzumab) and Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Herceptin (Trastuzumab) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Herceptin (Trastuzumab) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
United States market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Herceptin (Trastuzumab) and Biosimilar players cover Roche, Amgen, Pfizer, Organon, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Herceptin (Trastuzumab) and Biosimilar Industry Forecast” looks at past sales and reviews total world Herceptin (Trastuzumab) and Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Herceptin (Trastuzumab) and Biosimilar sales for 2026 through 2032. With Herceptin (Trastuzumab) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Herceptin (Trastuzumab) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Herceptin (Trastuzumab) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Herceptin (Trastuzumab) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Herceptin (Trastuzumab) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Herceptin (Trastuzumab) and Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Herceptin (Trastuzumab) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Herceptin (Trastuzumab) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Brand
- Biosimilar
- Breast Cancer
- Stomach Cancer
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Amgen
- Pfizer
- Organon
- Teva
- Viatris
- What is the 10-year outlook for the global Herceptin (Trastuzumab) and Biosimilar market?
- What factors are driving Herceptin (Trastuzumab) and Biosimilar market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Herceptin (Trastuzumab) and Biosimilar market opportunities vary by end market size?
- How does Herceptin (Trastuzumab) and Biosimilar break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Herceptin (Trastuzumab) and Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Herceptin (Trastuzumab) and Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Herceptin (Trastuzumab) and Biosimilar Segment by Type
2.2.1 Brand
2.2.2 Biosimilar
2.2.3 Herceptin (Trastuzumab) and Biosimilar Sales by Type
2.2.3.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Type (2021-2026)
2.3 Herceptin (Trastuzumab) and Biosimilar Segment by Application
2.3.1 Breast Cancer
2.3.2 Stomach Cancer
2.3.3 Herceptin (Trastuzumab) and Biosimilar Sales by Application
2.3.3.1 Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2021-2026)
2.3.3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Herceptin (Trastuzumab) and Biosimilar Breakdown Data by Company
3.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Product Location Distribution
3.4.2 Players Herceptin (Trastuzumab) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Herceptin (Trastuzumab) and Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Herceptin (Trastuzumab) and Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.4 APAC Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.5 Europe Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.6 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country
5.1.1 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
5.2 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
5.3 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region
6.1.1 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2021-2026)
6.2 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
6.3 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Herceptin (Trastuzumab) and Biosimilar by Country
7.1.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
7.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
7.3 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar by Country
8.1.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar
10.3 Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
10.4 Industry Chain Structure of Herceptin (Trastuzumab) and Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Herceptin (Trastuzumab) and Biosimilar Distributors
11.3 Herceptin (Trastuzumab) and Biosimilar Customer
12 WORLD FORECAST REVIEW FOR HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size Forecast by Region
12.1.1 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Type (2027-2032)
12.7 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Organon
13.4.1 Organon Company Information
13.4.2 Organon Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Organon Main Business Overview
13.4.5 Organon Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Herceptin (Trastuzumab) and Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Herceptin (Trastuzumab) and Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Herceptin (Trastuzumab) and Biosimilar Segment by Type
2.2.1 Brand
2.2.2 Biosimilar
2.2.3 Herceptin (Trastuzumab) and Biosimilar Sales by Type
2.2.3.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Type (2021-2026)
2.3 Herceptin (Trastuzumab) and Biosimilar Segment by Application
2.3.1 Breast Cancer
2.3.2 Stomach Cancer
2.3.3 Herceptin (Trastuzumab) and Biosimilar Sales by Application
2.3.3.1 Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2021-2026)
2.3.3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Herceptin (Trastuzumab) and Biosimilar Breakdown Data by Company
3.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Product Location Distribution
3.4.2 Players Herceptin (Trastuzumab) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Herceptin (Trastuzumab) and Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Herceptin (Trastuzumab) and Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Herceptin (Trastuzumab) and Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.4 APAC Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.5 Europe Herceptin (Trastuzumab) and Biosimilar Sales Growth
4.6 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country
5.1.1 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
5.2 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
5.3 Americas Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region
6.1.1 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2021-2026)
6.2 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
6.3 APAC Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Herceptin (Trastuzumab) and Biosimilar by Country
7.1.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
7.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
7.3 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar by Country
8.1.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar
10.3 Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
10.4 Industry Chain Structure of Herceptin (Trastuzumab) and Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Herceptin (Trastuzumab) and Biosimilar Distributors
11.3 Herceptin (Trastuzumab) and Biosimilar Customer
12 WORLD FORECAST REVIEW FOR HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size Forecast by Region
12.1.1 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Type (2027-2032)
12.7 Global Herceptin (Trastuzumab) and Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Organon
13.4.1 Organon Company Information
13.4.2 Organon Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Organon Main Business Overview
13.4.5 Organon Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
13.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Herceptin (Trastuzumab) and Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Herceptin (Trastuzumab) and Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Brand
Table 4. Major Players of Biosimilar
Table 5. Global Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Herceptin (Trastuzumab) and Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Herceptin (Trastuzumab) and Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Herceptin (Trastuzumab) and Biosimilar Products Offered
Table 22. Herceptin (Trastuzumab) and Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Herceptin (Trastuzumab) and Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Herceptin (Trastuzumab) and Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Herceptin (Trastuzumab) and Biosimilar
Table 52. Key Market Challenges & Risks of Herceptin (Trastuzumab) and Biosimilar
Table 53. Key Industry Trends of Herceptin (Trastuzumab) and Biosimilar
Table 54. Herceptin (Trastuzumab) and Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Herceptin (Trastuzumab) and Biosimilar Distributors List
Table 57. Herceptin (Trastuzumab) and Biosimilar Customer List
Table 58. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Roche Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Roche Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 74. Roche Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Roche Main Business
Table 76. Roche Latest Developments
Table 77. Amgen Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 79. Amgen Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Pfizer Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 84. Pfizer Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Organon Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Organon Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 89. Organon Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Organon Main Business
Table 91. Organon Latest Developments
Table 92. Teva Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Teva Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 94. Teva Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Teva Main Business
Table 96. Teva Latest Developments
Table 97. Viatris Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 99. Viatris Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
Table 1. Herceptin (Trastuzumab) and Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Herceptin (Trastuzumab) and Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Brand
Table 4. Major Players of Biosimilar
Table 5. Global Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Herceptin (Trastuzumab) and Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Herceptin (Trastuzumab) and Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Herceptin (Trastuzumab) and Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Herceptin (Trastuzumab) and Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Herceptin (Trastuzumab) and Biosimilar Products Offered
Table 22. Herceptin (Trastuzumab) and Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Herceptin (Trastuzumab) and Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Herceptin (Trastuzumab) and Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Herceptin (Trastuzumab) and Biosimilar
Table 52. Key Market Challenges & Risks of Herceptin (Trastuzumab) and Biosimilar
Table 53. Key Industry Trends of Herceptin (Trastuzumab) and Biosimilar
Table 54. Herceptin (Trastuzumab) and Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Herceptin (Trastuzumab) and Biosimilar Distributors List
Table 57. Herceptin (Trastuzumab) and Biosimilar Customer List
Table 58. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Herceptin (Trastuzumab) and Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Herceptin (Trastuzumab) and Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Herceptin (Trastuzumab) and Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Roche Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Roche Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 74. Roche Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Roche Main Business
Table 76. Roche Latest Developments
Table 77. Amgen Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 79. Amgen Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Pfizer Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 84. Pfizer Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Organon Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Organon Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 89. Organon Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Organon Main Business
Table 91. Organon Latest Developments
Table 92. Teva Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Teva Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 94. Teva Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Teva Main Business
Table 96. Teva Latest Developments
Table 97. Viatris Basic Information, Herceptin (Trastuzumab) and Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Herceptin (Trastuzumab) and Biosimilar Product Portfolios and Specifications
Table 99. Viatris Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
LIST OF FIGURES
Figure 1. Picture of Herceptin (Trastuzumab) and Biosimilar
Figure 2. Herceptin (Trastuzumab) and Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Herceptin (Trastuzumab) and Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Herceptin (Trastuzumab) and Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Brand
Figure 12. Product Picture of Biosimilar
Figure 13. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Herceptin (Trastuzumab) and Biosimilar Consumed in Breast Cancer
Figure 16. Global Herceptin (Trastuzumab) and Biosimilar Market: Breast Cancer (2021-2026) & (K Units)
Figure 17. Herceptin (Trastuzumab) and Biosimilar Consumed in Stomach Cancer
Figure 18. Global Herceptin (Trastuzumab) and Biosimilar Market: Stomach Cancer (2021-2026) & (K Units)
Figure 19. Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2025)
Figure 20. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application in 2026
Figure 21. Herceptin (Trastuzumab) and Biosimilar Sales by Company in 2026 (K Units)
Figure 22. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company in 2026
Figure 23. Herceptin (Trastuzumab) and Biosimilar Revenue by Company in 2026 ($ millions)
Figure 24. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company in 2026
Figure 25. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 28. Americas Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 29. APAC Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 30. APAC Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. Europe Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 32. Europe Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country in 2026
Figure 36. Americas Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 37. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 38. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 39. United States Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region in 2026
Figure 44. APAC Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Region (2021-2026)
Figure 45. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 46. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 47. China Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. India Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country in 2026
Figure 55. Europe Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 56. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 57. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 58. Germany Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 59. France Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 66. Egypt Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar in 2026
Figure 72. Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
Figure 73. Industry Chain Structure of Herceptin (Trastuzumab) and Biosimilar
Figure 74. Channels of Distribution
Figure 75. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 76. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Herceptin (Trastuzumab) and Biosimilar
Figure 2. Herceptin (Trastuzumab) and Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Herceptin (Trastuzumab) and Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Herceptin (Trastuzumab) and Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Brand
Figure 12. Product Picture of Biosimilar
Figure 13. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Herceptin (Trastuzumab) and Biosimilar Consumed in Breast Cancer
Figure 16. Global Herceptin (Trastuzumab) and Biosimilar Market: Breast Cancer (2021-2026) & (K Units)
Figure 17. Herceptin (Trastuzumab) and Biosimilar Consumed in Stomach Cancer
Figure 18. Global Herceptin (Trastuzumab) and Biosimilar Market: Stomach Cancer (2021-2026) & (K Units)
Figure 19. Global Herceptin (Trastuzumab) and Biosimilar Sale Market Share by Application (2025)
Figure 20. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application in 2026
Figure 21. Herceptin (Trastuzumab) and Biosimilar Sales by Company in 2026 (K Units)
Figure 22. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Company in 2026
Figure 23. Herceptin (Trastuzumab) and Biosimilar Revenue by Company in 2026 ($ millions)
Figure 24. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Company in 2026
Figure 25. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 28. Americas Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 29. APAC Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 30. APAC Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. Europe Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 32. Europe Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country in 2026
Figure 36. Americas Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 37. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 38. Americas Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 39. United States Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region in 2026
Figure 44. APAC Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Region (2021-2026)
Figure 45. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 46. APAC Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 47. China Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. India Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country in 2026
Figure 55. Europe Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2021-2026)
Figure 56. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 57. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 58. Germany Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 59. France Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2021-2026)
Figure 66. Egypt Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Herceptin (Trastuzumab) and Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar in 2026
Figure 72. Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
Figure 73. Industry Chain Structure of Herceptin (Trastuzumab) and Biosimilar
Figure 74. Channels of Distribution
Figure 75. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 76. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share Forecast by Application (2027-2032)
